Eupraxia Piotroski F Score

EPRXF -  USA Stock  

USD 2.30  0.00  0.00%

This module uses fundamental data of Eupraxia Pharmaceuticals to approximate its Piotroski F score. Eupraxia Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Eupraxia Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Eupraxia Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Eupraxia Pharmaceuticals Altman Z Score, Eupraxia Pharmaceuticals Correlation, Eupraxia Pharmaceuticals Valuation, as well as analyze Eupraxia Pharmaceuticals Alpha and Beta and Eupraxia Pharmaceuticals Hype Analysis.

Eupraxia Piotroski F Score 

 
Refresh
At this time, it appears that Eupraxia Pharmaceuticals' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
0.0
Piotroski F Score - Unavailable
1
Current Return On Assets
N/A
2
Change in Return on Assets
N/A
3
Cash Flow Return on Assets
N/A
4
Current Quality of Earnings (accrual)
N/A
5
Asset Turnover Growth
N/A
6
Current Ratio Change
N/A
7
Long Term Debt Over Assets Change
N/A
8
Change In Outstending Shares
N/A
9
Change in Gross Margin
N/A

Eupraxia Pharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Eupraxia Pharmaceuticals is to make sure Eupraxia is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Eupraxia Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Eupraxia Pharmaceuticals' financial numbers are properly reported.

About Eupraxia Pharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

About Eupraxia Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Eupraxia Pharmaceuticals Investors Sentiment

The influence of Eupraxia Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Eupraxia. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eupraxia Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eupraxia Pharmaceuticals' short interest history, or implied volatility extrapolated from Eupraxia Pharmaceuticals options trading.

Current Sentiment - EPRXF

Eupraxia Pharmaceuticals Investor Sentiment

Macroaxis portfolio users are insensible in their opinion about investing in Eupraxia Pharmaceuticals. What is your opinion about investing in Eupraxia Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Eupraxia Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eupraxia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Eupraxia Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Eupraxia Pharmaceuticals and Regeneron Pharmaceuticals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Eupraxia Pharmaceuticals Altman Z Score, Eupraxia Pharmaceuticals Correlation, Eupraxia Pharmaceuticals Valuation, as well as analyze Eupraxia Pharmaceuticals Alpha and Beta and Eupraxia Pharmaceuticals Hype Analysis. Note that the Eupraxia Pharmaceuticals information on this page should be used as a complementary analysis to other Eupraxia Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Eupraxia OTC Stock analysis

When running Eupraxia Pharmaceuticals price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Eupraxia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. If investors know Eupraxia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eupraxia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eupraxia Pharmaceuticals is measured differently than its book value, which is the value of Eupraxia that is recorded on the company's balance sheet. Investors also form their own opinion of Eupraxia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eupraxia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eupraxia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eupraxia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eupraxia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Eupraxia Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eupraxia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.